Axinn Wins Dismissal of Yeshiva University from Antitrust Conspiracy Class Action
February 24, 2004
Axinn recently secured an important victory for client Yeshiva University when Judge Paul L. Friedman of the D.C. District Court dismissed Yeshiva with prejudice from a purported class action lawsuit alleging that the medical community is conspiring to restrain competition in the market for medical residents in violation of Section 1 of the Sherman Act. According to the plaintiffs’ complaint, a conspiracy exists between organizations and associations that administer graduate medical education and the hospitals, medical schools and other organizations that offer or sponsor medical residency programs. The alleged purpose of this conspiracy is to fix, depress, standardize and stabilize resident physician compensation and other terms of employment. Yeshiva was accused of participating in the alleged conspiracy through its role as a sponsor of medical residency programs. As a sponsor, Yeshiva monitors residency program compliance with the requirements of the Accreditation Council for Graduate Medical Education (“ACGME”). Yeshiva, however, does not own or operate a hospital or employ medical residents. In its motion to dismiss, Yeshiva argued, among other things, that the plaintiffs failed to connect Yeshiva to the alleged conspiracy. Judge Friedman agreed. After carefully reviewing the complaint, Judge Friedman observed that the only allegations that could even arguably link Yeshiva to the alleged conspiracy were the allegations related to the ACGME standards themselves. Judge Friedman, however, properly refused to infer from those generalized allegations that a separate entity, whose only role was to monitor ACGME-accredited medical residencies on behalf of the ACGME, participated in the alleged conspiracy.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
Turning Up the Heat: Federal Circuit Sets the Temperature for pH Measurements in Precedential Opinion
Axinn Viewpoints
Intellectual Property
Axinn Represents Tecomet in Closing of Merger with Orchid Orthopedic
Deals & Cases
Antitrust
Recent Benchmarking Suits Highlight DOJ Enforcement Risks
Byline Articles
Antitrust
“Old Crime, New Code” – DOJ Outlines its Views on When Software and AI Can Facilitate Collusion
Axinn Viewpoints
Antitrust
